Legend Biotech ROA 2019-2021 | LEGN

Current and historical return on assets (ROA) values for Legend Biotech (LEGN) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Legend Biotech ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2021-06-30 $-0.30B $0.88B -40.82%
2021-03-31 $-0.34B $0.62B -48.40%
2020-12-31 $-0.30B $0.72B -47.35%
2020-09-30 $-0.31B $0.71B -58.08%
2020-06-30 $-0.27B $0.77B -76.02%
2020-03-31 $-0.17B $0.37B -101.07%
2019-12-31 $-0.13B $0.29B -184.72%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $7.681B $0.076B
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in Cayman Islands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76